1179149-30-4 Usage
Description
6-Chloroisoquinoline-1-carboxylic acid, also known as 6-Chloro-1H-isoquinoline-1-carboxylic acid, is a chlorinated derivative of isoquinoline with the molecular formula C10H6ClNO2. It is a white to off-white solid with a melting point of around 218-220°C.
Uses
Used in Pharmaceutical Industry:
6-Chloroisoquinoline-1-carboxylic acid is used as a building block for the synthesis of various pharmaceuticals and agrochemicals. It serves as a key intermediate in the production of antihypertensive and anti-inflammatory drugs.
Used in Antimicrobial Applications:
6-Chloroisoquinoline-1-carboxylic acid has been studied for its potential antimicrobial properties, making it a candidate for use in applications targeting the control and prevention of microbial infections.
Used in Antitumor Applications:
6-Chloroisoquinoline-1-carboxylic acid has also been investigated for its potential antitumor properties, indicating its possible use in the development of cancer treatments and therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 1179149-30-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,7,9,1,4 and 9 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1179149-30:
(9*1)+(8*1)+(7*7)+(6*9)+(5*1)+(4*4)+(3*9)+(2*3)+(1*0)=174
174 % 10 = 4
So 1179149-30-4 is a valid CAS Registry Number.
1179149-30-4Relevant articles and documents
HEPATITIS C VIRUS INHIBITORS
-
Paragraph 0523; 0555, (2017/07/05)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 113, (2012/02/15)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 119, (2011/06/16)
The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.
